英菲格拉替尼的适应症

Infigratinib is a kinase inhibitor targeting FGFR1-3, which provides a new treatment option for patients with cholangiocarcinoma with FGFR2 gene abnormalities. The drug works by specifically inhibiting the growth signaling pathways of tumor cells, but its use requires strict genetic testing and medication management. This article will comprehensively analyze the clinical application characteristics of infigratinib from three aspects: indications, efficacy and effects, and contraindications, to help patients and medical professionals better understand this innovative targeted drug.

Indications of Infigratinib

The clinical application of Infigratinib has clear targeting and population selectivity.

Specific genotype cholangiocarcinoma

Applicable to adult patients with unresectable locally advanced or metastatic cholangiocarcinoma confirmed to have FGFR2 fusion or rearrangement by FDA-approved testing methods. This indication is based on the concept of precision medicine and is only effective against specific genetic mutations.

Second-line treatment options

This provides new treatment opportunities for patients with advanced cholangiocarcinoma who have failed at least one first-line systemic treatment. Clinical studies show that its objective response rate is significantly better than traditional chemotherapy.

Accelerated approval status

This indication is accelerated approval based on objective response rate and response duration, and the long-term survival benefit still needs further verification. This requires continuous evaluation of efficacy during medication administration.

The indications of infigratinib reflect the trend of modern cancer treatment towards precision and individualization.

Efficacy and role of Infigratinib

Infigratinib exerts anti-tumor effects through multiple mechanisms.

Targeted inhibition of the FGFR signaling pathway

Selectively inhibits the tyrosine kinase activity of FGFR1-3 and blocks downstream pro-proliferation signaling. This specific effect makes it highly effective against tumors with abnormal FGFR2.

Induce tumor cell apoptosis

By interfering with cell cycle regulation and metabolic reprogramming, it promotes programmed death of tumor cells. Clinical data shows that the tumor shrinkage rate is high.

Delay disease progression

The median progression-free survival period is longer than that of traditional regimens, significantly improving patients’ quality of life, and some patients can achieve long-term disease stability.

These mechanisms of action together form the pharmacological basis of infigratinib in the treatment of cholangiocarcinoma.

Contraindications of Infigratinib

Infigratinib should be disabled or used with caution under certain circumstances.

Patients with negative gene testing

It is prohibited for patients with undetected FGFR2 fusion or rearrangement. This group of people will hardly benefit from treatment.

Absolute contraindications during pregnancy

Animal experiments show that the drug has clear embryotoxicity and can cause fetal malformations. Women of childbearing age need to use strict contraception during treatment.

Severe hepatic and renal insufficiency

It is contraindicated in patients with Child-Pugh Class C hepatic impairment and end-stage renal disease due to lack of safety and efficacy data.

Drug interaction restrictions

It is prohibited to combine with strong CYP3A inhibitors or inducers. Such drugs will significantly affect the plasma concentration of infigratinib.

Patients should strictly abide by the contraindications and take medication under the guidance of a professional physician.